Australian-developed bowel cancer test approved in China
Biotech company Clinical Genomics has received China Food and Drug Administration (CFDA) approval for the commercialisation of InSure FIT, its faecal immunochemical test for colorectal cancer.
Warren Bingham, Clinical Genomics VP, Asia Pacific, said the CFDA approval represents another international vote of confidence in the company’s cancer testing solutions. It comes 16 months after Clinical Genomics appointed clinical diagnostics company BioChain Group as its exclusive Chinese distribution partner, and 17 years after the first person was screened using InSure FIT.
“Screening with faecal immunochemical tests is a guideline-endorsed option being adopted worldwide based on clear evidence that it will save lives,” said Bingham. “Governments are actively seeking affordable, effective and user-friendly cancer screening solutions for their communities.
“The InSure FIT ‘brush’ is easy to use and is designed for large screening programs. This test is ideal for large countries such as China with regional and remote communities that may not otherwise have accessible screening options.”
Clinical Genomics’ goal is to position the InSure FIT as being suitable for integration into the China Cancer Screening Program recently announced by the Chinese Government.
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
